Patents by Inventor Alessandro Grattoni

Alessandro Grattoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250108000
    Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
    Type: Application
    Filed: October 15, 2024
    Publication date: April 3, 2025
    Inventors: Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu
  • Patent number: 12151021
    Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: November 26, 2024
    Assignee: THE METHODIST HOSPITAL SYSTEM
    Inventors: Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu
  • Publication number: 20240148968
    Abstract: A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mes
    Type: Application
    Filed: November 10, 2023
    Publication date: May 9, 2024
    Inventors: Marco Farina, Robert Lyle Hood, Alessandro Grattoni
  • Patent number: 11813432
    Abstract: A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mes
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: November 14, 2023
    Assignee: The Methodist Hospital
    Inventors: Marco Farina, Robert Lyle Hood, Alessandro Grattoni
  • Publication number: 20230310310
    Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
    Type: Application
    Filed: February 27, 2023
    Publication date: October 5, 2023
    Inventors: Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu
  • Publication number: 20230265371
    Abstract: The present disclosure is directed to devices used for transplanting or recruiting cells, in addition to methods for making said devices and for using said devices in the treatment of medical disorders.
    Type: Application
    Filed: June 24, 2021
    Publication date: August 24, 2023
    Inventors: Ying Xuan Chua, Alessandro Grattoni, Jesus Paez Mayorga, Simone Capuani
  • Patent number: 11590072
    Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: February 28, 2023
    Assignee: THE METHODIST HOSPITAL SYSTEM
    Inventors: Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu
  • Publication number: 20230043407
    Abstract: Devices and methods for controlling molecular transport are disclosed herein. The devices include a membrane having a plurality of nanochannels extending therethrough. The membrane has an inner electrically conductive layer and an outer dielectric layer. The outer dielectric layer creates an insulative barrier between the electrically conductive layer and the contents of the nanochannels. At least one electrical contact region is positioned on a surface of the membrane. The electrical contact region exposes the electrically conductive layer of the membrane for electrical coupling to external electronics. When the membrane is at a first voltage, molecules flow through the nanochannels at a first release rate. When the membrane is at a second voltage, charge accumulation within the nanochannels modulates the flow of molecules through the nanochannels to a second release rate that is different than the first release rate.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 9, 2023
    Applicant: THE METHODIST HOSPITAL SYSTEM
    Inventors: Alessandro Grattoni, Xuewu Liu, Mauro Ferrari
  • Patent number: 11565094
    Abstract: Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: January 31, 2023
    Assignee: THE METHODIST HOSPITAL SYSTEM
    Inventors: Marco Farina, Andrea Ballerini, Daniel W. Fraga, Usha Ramachandran Thekkedath, Omaima M. Sabek, Ahmed Osama Gaber, Alessandro Grattoni
  • Publication number: 20230023802
    Abstract: The present disclosure provides solid drug formulations, in particular to stabilized formulations of phosphonamidate-containing drugs, as well as methods for loading drug delivery devices with solid formulations.
    Type: Application
    Filed: December 7, 2020
    Publication date: January 26, 2023
    Applicant: THE METHODIST HOSPITAL SYSTEM
    Inventors: Antons Sizovs, Fernanda Paola Pons Faudoa, Alessandro Grattoni
  • Publication number: 20220040406
    Abstract: A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mes
    Type: Application
    Filed: March 23, 2021
    Publication date: February 10, 2022
    Inventors: Marco Farina, Robert Lyle Hood, Alessandro Grattoni
  • Publication number: 20210196624
    Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
    Type: Application
    Filed: May 21, 2020
    Publication date: July 1, 2021
    Inventors: Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu
  • Publication number: 20210187260
    Abstract: Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.
    Type: Application
    Filed: October 17, 2018
    Publication date: June 24, 2021
    Inventors: Marco FARINA, Andrea BALLERINI, Daniel W. FRAGA, Usha Ramachandran THEKKEDATH, Omaima M. SABEK, Ahmed Osama GABER, Alessandro GRATTONI
  • Patent number: 10987500
    Abstract: A nanochannel delivery device and method of manufacturing and use. The nanochannel delivery device comprises an inlet, an outlet, electrodes and a nanochannel. The nanochannel may be oriented parallel to the primary plane of the nanochannel delivery device. The inlet and outlet may be in direct fluid communication with the nanochannel.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 27, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Daniel Fine, Alessandro Grattoni, Mauro Ferrari, Xuewu Liu, Randal Goodall, Sharath Hosali
  • Patent number: 10953154
    Abstract: A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mes
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: March 23, 2021
    Assignee: The Methodist Hospital
    Inventors: Marco Farina, Robert Lyle Hood, Alessandro Grattoni
  • Publication number: 20180280617
    Abstract: A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mes
    Type: Application
    Filed: October 19, 2016
    Publication date: October 4, 2018
    Inventors: Marco Farina, Robert Lyle Hood, Alessandro Grattoni
  • Publication number: 20180125780
    Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
    Type: Application
    Filed: May 16, 2016
    Publication date: May 10, 2018
    Inventors: Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu
  • Patent number: 9526824
    Abstract: A nanochannel delivery device and method of manufacturing and use. The nanochannel delivery device comprises an inlet, an outlet, and a nanochannel. The nanochannel may be oriented parallel to the primary plane of the nanochannel delivery device. The inlet and outlet may be in direct fluid communication with the nanochannel.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 27, 2016
    Assignees: The Board of Regents of the University of Texas System, The Ohio State University Research Foundation
    Inventors: Mauro Ferrari, Xuewu Liu, Alessandro Grattoni, Daniel Fine, Randy Goodall, Sharath Hosali, Ryan Medema, Lee Hudson
  • Publication number: 20150246174
    Abstract: A capsule configured for in vivo refilling of a therapeutic agent. In certain embodiments, the capsule may contain methotrexate.
    Type: Application
    Filed: March 16, 2015
    Publication date: September 3, 2015
    Applicants: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Mauro Ferrari, Xuewu Liu, Alessandro Grattoni, Randy Goodall, Lee Hudson
  • Patent number: 9005185
    Abstract: A capsule configured for in vivo refilling of a therapeutic agent. In certain embodiments, the capsule may contain methotrexate.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: April 14, 2015
    Assignees: The Board of Regents of the University of Texas System, The Ohio State University Research Foundation
    Inventors: Mauro Ferrari, Xuewu Liu, Alessandro Grattoni, Randy Goodall, Lee Hudson